0960-894X(95)00009-7

Piperidine-Ether Based hNK₁ Antagonists 2: Investigation of the Effect of N-Substitution

T. Harrison*, A.P. Owens, B. J. Williams, C. J. Swain, R. Baker, P. H. Hutson\$, S. Sadowski\$ and M. A. Cascieri\$.

Department of Medicinal Chemistry, \$Department of Biochemistry, Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 20R, U.K.

\$Department of Molecular Pharmacology and Biochemistry, Merck Research Laboratories, Rahway, New Jersey 07065

Abstract: The effect of nitrogen substitution on the binding affinity of the piperidine-ether substance P antagonist L-733,060 for the hNK₁ receptor and L-type Ca²⁺ channel is discussed.

A recent report from these laboratories has described the synthesis of a series of piperidine-ether based human NK_1 (hNK₁) antagonists (eg L-733,060)¹. Although L-733,060 (hNK₁ IC₅₀ 0.87nM) shows high affinity for the hNK₁ receptor and excellent selectivity with respect to the other neurokinin receptors (hNK₂, hNK₃, IC₅₀ > 1000nM) it also shows modest affinity for the L-type Ca^{2+} channel (inhibition of [³H] diltiazem binding in rabbit skeletal muscle, IC₅₀ = 0.76 μ M)². Binding at the L-type Ca^{2+} channel has been observed in several other series of hNK₁ antagonists which contain a basic amino group^{3,4}, and it has been suggested that calcium channel blockade is responsible for the adverse cardiovascular effects of the quinuclidine-based hNK₁ antagonists such as CP 96.345³.

L-733,060

We have recently shown in the acyclic benzhydryl amino-ether series of hNK₁ antagonists that substitution on nitrogen with electron-withdrawing polar substituents leads to an *increase* in hNK₁ affinity and a dramatic *decrease* in binding at the L-type Ca^{2+} channel⁴. In this communication we describe the effects of N-substitution in the piperidine ether series and show that a similar strategy can be used to reduce Ca^{2+} activity without compromising affinity at the hNK₁ receptor.

The synthesis of a range of N-alkyl, acyl and substituted alkyl derivatives of L-733,060 is shown in Scheme 1. The alkyl substituted piperidines were prepared from L-733,060 1 by reductive alkylation (4) or by reaction with the appropriate alkyl halide (5, 7, 11) or with methyl acrylate (10) followed by functional group modification (8, 9, 12, 13). The acyl analogues (2, 3, 6) were prepared by reaction of L-733,060 with the appropriate acid chloride. The affinities of the various derivatives for the hNK₁ receptor are summarised in Table 1.

It can be seen that although simple alkyl (eg 4,5) and acyl (6) substitution leads to a decrease in binding affinity, the introduction of polar alkyl substituents (eg L-736,281) is well tolerated. Furthermore, binding affinity at the Ca^{2+} channel is all but abolished, in line with the decreased pK_a of the piperidine nitrogen (L-733,060, pK_a=8.3, L-736,281, pK_a=5.4,)⁶. Saponification of (7) provides the amino-acid (8) which shows much reduced affinity at the hNK₁ receptor compared to either the ester or the amide. The substitution of the methylene spacer (in 7 and L-736,281) for a carbonyl group leads to the keto ester (3) and the keto-amide (2) respectively which again show much reduced affinity at the hNK₁ receptor. The possibility that this reduction in affinity is as a result of a conformational change in the piperidine ring induced by A^{1,3} strain⁷ is currently being investigated.

Reagents: (i) MeO₂CCOCI, Et₃N, CH₂Cl₂; (ii) NH₃, EtOH; (iii) HCHO, NaCNBH₃, MeOH, AcOH; (iv) PhCH₂Br, K₂CO₃, DMF; (y) AcCI, pyridine, CH₂Cl₂; (vi) BrCH₂CO₂Me, K₂CO₃, DMF; (vii) KOH, MeOH; (viii) CH₂=CHCO₂Me (neat); (ix) Br(CH₂)₃CO₂Me, K₂CO₃, DMF; (x) MeNH₂, MeOH; (xi) 1-(3-dimethylaminopropyl)-3-ethyl carbodlimide HCl, hydroxybenzotriazole, MeNH, DMF.

Compound 1 (L-733.060) 2 3 4 5 6 7 8 9 (L-736,281)	hNK ₁ (IC ₅₀ /nM) ^{5,11} 0.87 ± 0.51 25 ± 7 68 ± 27 14 ± 4 110 ± 66 35 ± 18 2.8 ± 1.8 85 ± 13 1.3 ± 0.5	Ca ²⁺ binding ^{2,10} IC ₅₀ 760nM 0% @ 5μM 0% @ 5μM IC ₅₀ 720nM IC ₅₀ 4.1μM 0% @ 5μM IC ₅₀ 26μM 7% @ 5μM
_		- ,
9 (L-736,281) 10	1.3 ± 0.5 1.8 ± 0.4	16% @ 30μM 98% @ 5μM
11	2.7 ± 0.2	98% @ 5μM
12	0.63 ± 0.05	0% @ 5μΜ
13	0.3 ± 0.07	0% @ 5µМ

Table 1

Having confirmed that in the piperidine series we could reduce binding affinity at the L-type Ca^{2+} channel whilst retaining high affinity at the hNK₁ receptor we next sought to investigate the effect of increasing the length of the methylene spacer between the piperidine nitrogen and the carboxamido group in L-736,281. Accordingly, the homologated amides (10) and (11) were prepared as shown in Scheme 1. The binding data is summarised in Table 1.

It can be seen that homologation of the amide in L-736,281 by one or two methylene units has minimal effect on the binding affinity. Importantly however, as the length of the tether is increased there is a marked increase in Ca^{2+} channel binding, in line with the increased pK_a of the piperidine nitrogen. (L-736,281, pK_a=5.4, 10, pK_a=6.5). Thus in this series of piperidine derivatives the one carbon spacer would appear to be optimal for high-affinity binding at the hNK₁ receptor and low affinity binding at the L-type Ca^{2+} channel.

We were also interested in establishing whether the carboxamido function in (9) was functioning as a H-bond donor by the preparation of the corresponding N-methyl and N,N-dimethyl analogues (12) and (13). (Scheme 1). It can be seen from Table 1 that there is no decrease in hNK₁ binding affinity as the H-bonding capability of the amide is removed. Clearly however, in each of these derivatives the amide remains as a powerful H-bond acceptor.

It is interesting to compare the binding affinity of L-736,281 with that of (14), an analogous compound from the piperidine amine series⁸. Whereas in the piperidine ether series the incorporation of electron-withdrawing substituents on the piperidine nitrogen can be used to modulate the basicity of the nitrogen without affecting hNK₁ binding affinity, in the piperidine amine series binding affinity at the hNK₁ receptor is severely compromised ((±)-14: hNK₁ IC₅₀ 227nM; cf. CP-99,994, IC₅₀ 0.6nM)⁹.

Acknowledgement: We thank A. Watt for pK_a determinations, S. Patel for providing some of the Ca^{2+} channel binding data and Simon Owen for preparing (14).

References and Notes

- 1. Harrison, T.; Williams, B.J.; Swain, C.J.; Ball, R.G. Bioorganic and Medicinal Chem. Lett. 1994, 4, 2545.
- Ca²⁺ channel binding was determined using a method similar to that described by: Reynolds, I.; Snowman, A.M.; Snyder, S.H. J. Pharmac. Exp. Therap. 1986, 237, 731.
- 3. Schmidt, A.W.; McLean, S.; Heym, J. European J. Pharmacol.. 1992, 219, 491.
- Williams, B.J.; Teall, M.; McKenna, J.; Harrison, T.; Swain, C.J.; Cascieri, M.A.;
 Sadowski, S.; Strader, C.; Baker, R. Bioorganic and Medicinal Chem. Lett., 1994, 4, 1903.
- 5. The affinities of the compounds for the hNK₁ receptor were determined by displacement of [125I] Substance P from hNK-1 receptor in CHO cells: see (i) Cascieri, M.A.; Ber, E.; Fong, T.M.; Sadowski, S.; Bansal, A.; Swain, C. J.; Seward, E.; Frances, B.; Burns, D.; Strader, C.D. Mol. Pharm.. 1992, 42, 458. (ii) Fong, T.M.; Anderson, S.A.; Yuh, H.; Huang, R.R.C.; Strader, C.D. Mol. Pharm.. 1992, 41, 24.
- pK_a measurements were made using the log P-pH method, see: Schaper. K.J. J. Chem. Res. (S) 1979, 357.
- 7. Hoffmann, R. W. Chem Rev. 1989, 89, 1841.
- 8. Desai, M.C.; Rosen, T.J. EP 436 334 A2.
- It should be noted that L-736,281 and CP-99,994 are single enantiomers whilst 14 is a racemate.
- All experiments were carried out using diltiazem as a positive control, n=1 for all experiments.
- n=3 for all compounds except L-733,060 for which n=7. Values quoted are mean IC₅₀ values ± SEM.

(Received in Belgium 29 July 1994; accepted 1 December 1994)